

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



New Ray Medicine
新銳醫藥

New Ray Medicine International Holding Limited
新銳醫藥國際控股有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 6108)

GRANT OF SHARE OPTIONS

This announcement is made pursuant to Rule 17.06A of the Rules (“**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”).

The board (“**Board**”) of directors (“**Directors**”) of New Ray Medicine International Holding Limited (“**Company**”, together with its subsidiaries, the “**Group**”) announces that on 14 June 2022, the Company has granted to certain eligible persons (“**Grantees**”), subject to acceptance by the Grantees, share options (“**Options**”) to subscribe for an aggregate of 143,200,000 ordinary shares of HK\$0.05 each in the share capital of the Company (“**Shares**”) (upon exercise in full and subject to adjustment in accordance with the share option scheme adopted by the Company on 26 September 2013 (“**Share Option Scheme**”)) under the Share Option Scheme. Details of the Options are set out below:

Date of grant : 14 June 2022 (“**Date of Grant**”)

Exercise price of Options granted : HK\$0.287 per Share, being the highest of (i) the closing price of HK\$0.270 of the Shares on the Date of Grant; (ii) the average closing price of HK\$0.287 of the Shares for the five trading days immediately preceding the Date of Grant; and (iii) the nominal value of the Shares (being HK\$0.05 per Share)

Total number of Shares to be issued upon exercise in full of the Options granted : 143,200,000 Shares

Validity period of the Options : 14 June 2022 to 13 June 2027, both days inclusive
(subject to acceptance)

Consideration for the grant of the Options : HK\$1.00 to be paid by each Grantee upon the acceptance of the Options granted

As at the Date of Grant, the Company had 1,671,846,657 Shares in issue.

Among the Options granted, Options entitling the holders thereof to subscribe for an aggregate of 110,000,000 Shares were granted to employees of the Group and Options entitling the holders thereof to subscribe for an aggregate of 33,200,000 Shares were granted to two Directors. Details of the Options granted to the Grantees who are Directors are as follows:

Name of the Grantee	Capacity	Number of underlying Shares
Wang Qiuqin	Chairman and Executive Director	16,600,000
Chu Xueping	Executive Director	16,600,000

The grant of the Options to the above Directors has been reviewed and approved by the independent non-executive Directors in accordance with Rule 17.04(1) of the Listing Rules.

Save as disclosed above, none of the Grantees is a Director, chief executive or substantial shareholder of the Company, or any of their respective associate(s) (as defined under the Listing Rules).

By Order of the Board
New Ray Medicine International Holding Limited
Wang Qiuqin
Chairman & Executive Director

Hong Kong, 14 June 2022

As of the date of this announcement, the executive Directors are Ms. Wang Qiuqin, Mr. Huo Zhihong and Mr. Chu Xueping; and the independent non-executive Directors are Mr. Leung Chi Kin, Ms. Li Sin Ming, Ivy and Mr. Sy Lai Yin, Sunny.